Mechanisms and management of refractory coeliac disease
Open Access
- 8 September 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Gastroenterology & Hepatology
- Vol. 12 (10), 572-579
- https://doi.org/10.1038/nrgastro.2015.155
Abstract
A small subset of patients with coeliac disease become refractory to a gluten-free diet with persistent malabsorption and intestinal villous atrophy. The most common cause of this condition is inadvertent gluten exposure, but concomitant diseases leading to villous atrophy should also be considered and excluded. After exclusion of these conditions, patients are referred to as having refractory coeliac disease, of which two categories are recognized based on the absence (type I) or presence (type II) of a clonal expansion of premalignant intraepithelial lymphocyte population with a high potential for transformation into an overt enteropathy-associated T-cell lymphoma. Type I disease usually has a benign course that can be controlled by mild immunosuppressive treatment, but type II can be more severe with cladribine with or without autologous stem cell transplantation effective as treatment. Patients who fail to respond to cladribine therapy, however, still have a high risk of malignant transformation. Insights into the immunophenotype of these cells and the recognition that type II disease is a low-grade, no-mass lymphoma opens avenues for new treatment strategies, including chemotherapeutic and immunomodulating strategies. This Review will provide an overview of refractory coeliac disease, discussing mechanisms, diagnosis and management.Keywords
This publication has 69 references indexed in Scilit:
- Update on the Diagnosis and Management of Refractory Coeliac DiseaseGastroenterology Research and Practice, 2013
- Serum parameters in the spectrum of coeliac disease: beyond standard antibody testing - a cohort studyBMC Gastroenterology, 2012
- Comparison of MR enteroclysis with video capsule endoscopy in the investigation of small-intestinal diseaseAbdominal Radiology, 2012
- Evaluation of Cladribine treatment in refractory celiac disease type IIWorld Journal of Gastroenterology, 2011
- IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease–associated inflammation and lymphomagenesisJCI Insight, 2010
- Gluten-Free Diet and Steroid Treatment Are Effective Therapy for Most Patients With Collagenous SprueClinical Gastroenterology and Hepatology, 2010
- Classification and management of refractory coeliac diseaseGut, 2010
- Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten‐free dietAlimentary Pharmacology & Therapeutics, 2009
- Clinical Staging and Survival in Refractory Celiac Disease: A Single Center ExperienceGastroenterology, 2009
- Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experienceGut, 2007